Bundling Drugs: The Risks Of Combining Copay Assistance

Eli Lilly’s program linking copay discounts for tirzepatide (Zepbound) to prescriptions for ixekizumab (Taltz) could constitute anticompetitive behavior that harms competition in unrelated markets without producing meaningful price competition. Th authors call on the FTC to evaluate such arrangements and urge Congress to regulate copay assistance programs in commercial insurance.